NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: W H Freeman; 2002.

  • By agreement with the publisher, this book is accessible by the search feature, but cannot be browsed.
Cover of Biochemistry

Biochemistry. 5th edition.

Show details

Section 21.5Glycogen Breakdown and Synthesis Are Reciprocally Regulated

We now return to the regulation of glycogen metabolism with a knowledge of both degradation and synthesis. Glycogen breakdown and synthesis are reciprocally regulated by a hormone-triggered cAMP cascade acting through protein kinase A (Figure 21.18). In addition to phosphorylating and activating phosphorylase kinase, protein kinase A adds a phosphoryl group to glycogen synthase, which leads to a decrease in enzymatic activity. This important control mechanism prevents glycogen from being synthesized at the same time that it is being broken down. How is the enzymatic activity reversed so that glycogen breakdown halts and glycogen synthesis begins?

Figure 21.18. Coordinate Control of Glycogen Metabolism.

Figure 21.18

Coordinate Control of Glycogen Metabolism. Glycogen metabolism is regulated, in part, by hormone-triggered cyclic AMP cascades: (A) glycogen degradation; (B) glycogen synthesis. Inactive forms are shown in red, and active ones in green. The sequence of (more...)

21.5.1. Protein Phosphatase 1 Reverses the Regulatory Effects of Kinases on Glycogen Metabolism

The changes in enzymatic activity produced by protein kinases are reversed by protein phosphatases. The hydrolysis of phosphorylated serine and threonine residues in proteins is catalyzed by protein phosphatases. One enzyme, termed protein phosphatase 1, plays key roles in regulating glycogen metabolism. PP1 inactivates phosphorylase kinase and phosphorylase a by dephosphorylating these enzymes. PP1 decreases the rate of glycogen breakdown: it reverses the effects of the phosphorylation cascade. Moreover, PP1 also removes the phosphoryl group from glycogen synthase b to convert it into the much more active a form. Hence, PP1 accelerates glycogen synthesis. PP1 is yet another molecular device for coordinating carbohydrate storage.

The complete complex of PP1 consists of three components: PP1 itself, a 37-kd catalytic subunit; a 123-kd RGl subunit that confers high affinity for glycogen; and inhibitor 1, a small regulatory subunit that, when phosphorylated, inhibits PP1. The importance of the RGl subunit is that it brings PP1, which is active only when associated with glycogen molecules, into proximity with its substrates.

How is the phosphatase activity of PP1 itself regulated? Consider the case in which glycogen degradation is predominant (Figure 21.19). In this case, PKA is active. Two components of PP1 are themselves substrates for protein kinase A. Phosphorylation of the RGl component by protein kinase A prevents RGl from binding the catalytic subunit of PP1. Consequently, activation of the cAMP cascade leads to the inactivation of PP1 because it can no longer bind its substrates. Phosphorylation of inhibitor 1 by protein kinase A blocks catalysis by PP1. Thus, when glycogen degradation is switched on by cAMP, the accompanying phosphorylation of inhibitor 1 keeps phosphorylase in the active a form and glycogen synthase in the inactive b form. The epinephrine-induced phosphorylation of the RGl subunit and inhibitor 1 are complementary devices for sustaining glycogen degradation.

Figure 21.19. Regulation of Protein Phosphatase 1 (PP1).

Figure 21.19

Regulation of Protein Phosphatase 1 (PP1). Phosphorylation of RGl by protein kinase A dissociates the catalytic subunit from the glycogen particle and hence the PP1 substrates. Inhibition is complete when the inhibitor subunit (I) is phosphorylated and (more...)

21.5.2. Insulin Stimulates Glycogen Synthesis by Activating Protein Phosphatase 1

How is glycogen synthesis stimulated? As stated earlier, the presence of glucagon signifies the starved state and initiates glycogen breakdown while inhibiting glycogen synthesis. When blood-glucose levels are high, insulin stimulates the synthesis of glycogen by triggering a pathway that activates protein phosphatase 1 (Figure 21.20). The first step in the action of insulin is its binding to a receptor tyrosine kinase in the plasma membrane. Multiple phosphorylations again serve as the instigation for a regulatory wave of dephosphorylations. The binding of insulin to its receptor leads to the activation of an insulin-sensitive protein kinase that phosphorylates the RGl subunit of PP1 at a site different from that modified by protein kinase A. This phosphorylation leads to the association of the RGl subunit with PP1 and the glycogen molecule. The consequent dephosphorylation of glycogen synthase, phosphorylase kinase, and phosphorylase promotes glycogen synthesis and blocks its degradation. Once again we see that glycogen synthesis and breakdown are coordinately controlled.

Figure 21.20. Insulin Activates Protein Phosphatase 1.

Figure 21.20

Insulin Activates Protein Phosphatase 1. Insulin triggers a cascade leading to the activation of protein phosphatase 1, which results in the stimulation of glycogen synthesis and inhibition of its breakdown. The activated receptor tyrosine kinase switches (more...)

21.5.3. Glycogen Metabolism in the Liver Regulates the Blood-Glucose Level

After a meal rich in carbohydrates, blood-glucose levels rise, leading to an increase in glycogen synthesis in the liver. Although insulin is the primary signal for glycogen synthesis, other, nonhormonal mechanisms also function in the liver. One signal is the concentration of glucose in the blood, which normally ranges from about 80 to 120 mg per 100 ml (4.4 – 6.7 mM). The liver senses the concentration of glucose in the blood and takes up or releases glucose accordingly. The amount of liver phosphorylase a decreases rapidly when glucose is infused (Figure 21.21). After a lag period, the amount of glycogen synthase a increases, which results in the synthesis of glycogen. In fact, phosphorylase a is the glucose sensor in liver cells. The binding of glucose to phosphorylase a shifts its allosteric equilibrium from the active R form to the inactive T form. This conformational change renders the phosphoryl group on serine 14 a substrate for protein phosphatase 1. It is significant that PP1 binds tightly to phosphorylase a but acts catalytically only when glucose induces the transition to the T form. Recall that the R ↔ T transition of muscle phosphorylase a is unaffected by glucose and is thus unaffected by the rise in blood-glucose levels (Section 21.2.2).

Figure 21.21. Blood Glucose Regulates Liver Glycogen Metabolism.

Figure 21.21

Blood Glucose Regulates Liver Glycogen Metabolism. The infusion of glucose into the bloodstream leads to the inactivation of phosphorylase, followed by the activation of glycogen synthase, in the liver. [After W. Stalmans, H. De Wulf, L. Hue, and H.-G. (more...)

How does glucose activate glycogen synthase? Phosphorylase b, in contrast with phosphorylase a, does not bind the phosphatase. Consequently, the conversion of a into b is accompanied by the release of PP1, which is then free to activate glycogen synthase (Figure 21.22). Removal of the phosphoryl group of inactive glycogen synthase b converts it into the active a form. Initially, there are about 10 phosphorylase a molecules per molecule of phosphatase. Hence, the activity of glycogen synthase begins to increase only after most of phosphorylase a is converted into b. This remarkable glucose-sensing system depends on three key elements: (1) communication between the serine phosphate and the allosteric site for glucose, (2) the use of PP1 to inactivate phosphorylase and activate glycogen synthase, and (3) the binding of the phosphatase to phosphorylase a to prevent the premature activation of glycogen synthase.

Figure 21.22. Glucose Regulation of Liver Glycogen Metabolism.

Figure 21.22

Glucose Regulation of Liver Glycogen Metabolism. Glucose binds to and inhibits glycogen phosphorylase a in the liver, leading to the dissociation and activation of protein phosphatase 1 (PP1) from glycogen phosphorylase a. The free PP1 dephosphorylates (more...)

21.5.4. A Biochemical Understanding of Glycogen-Storage Diseases Is Possible

Image caduceus.jpg Edgar von Gierke described the first glycogen-storage disease in 1929. A patient with this disease has a huge abdomen caused by a massive enlargement of the liver. There is a pronounced hypoglycemia between meals. Furthermore, the blood-glucose level does not rise on administration of epinephrine and glucagon. An infant with this glycogen-storage disease may have convulsions because of the low blood-glucose level.

The enzymatic defect in von Gierke disease was elucidated in 1952 by Carl and Gerty Cori. They found that glucose 6-phosphatase is missing from the liver of a patient with this disease. This was the first demonstration of an inherited deficiency of a liver enzyme. The liver glycogen is normal in structure but present in abnormally large amounts. The absence of glucose 6-phosphatase in the liver causes hypoglycemia because glucose cannot be formed from glucose 6-phosphate. This phosphorylated sugar does not leave the liver, because it cannot cross the plasma membrane. The presence of excess glucose 6-phosphate triggers an increase in glycolysis in the liver, leading to a high level of lactate and pyruvate in the blood. Patients who have von Gierke disease also have an increased dependence on fat metabolism. This disease can also be produced by a mutation in the gene that encodes the glucose 6-phosphate transporter. Recall that glucose 6-phosphate must be transported into the lumen of the endoplasmic reticulum to be hydrolyzed by phosphatase (Section 16.3.5). Mutations in the other three essential proteins of this system can likewise lead to von Gierke disease.

Seven other glycogen-storage diseases have been characterized (Table 21.1). In Pompe disease (type II), lysosomes become engorged with glycogen because they lack α-1,4-glucosidase, a hydrolytic enzyme confined to these organelles (Figure 21.23). The Coris elucidated the biochemical defect in another glycogen-storage disease (type III), which cannot be distinguished from von Gierke disease (type I) by physical examination alone. In type III disease, the structure of liver and muscle glycogen is abnormal and the amount is markedly increased. Most striking, the outer branches of the glycogen are very short. Patients having this type lack the debranching enzyme (α-1,6-glucosidase), and so only the outermost branches of glycogen can be effectively utilized. Thus, only a small fraction of this abnormal glycogen is functionally active as an accessible store of glucose.

Table 21.1. Glycogen-storage diseases.

Table 21.1

Glycogen-storage diseases.

Figure 21.23. Glycogen-Engorged Lysosome.

Figure 21.23

Glycogen-Engorged Lysosome. This electron micrograph shows skeletal muscle from an infant with type II glycogen-storage disease (Pompe disease). The lysosomes are filled with glycogen because of a deficiency in α-1,4-glucosidase, a hydrolytic (more...)

A defect in glycogen metabolism confined to muscle is found in McArdle disease (type V). Muscle phosphorylase activity is absent, and the patient's capacity to perform strenuous exercise is limited because of painful muscle cramps. The patient is otherwise normal and well developed. Thus, effective utilization of muscle glycogen is not essential for life. The results of phosphorus-31 nuclear magnetic resonance studies of these patients have been very informative. The pH of skeletal muscle cells of normal people drops during strenuous exercise because of the production of lactate. In contrast, the muscle cells of patients with McArdle disease become more alkaline during exercise because of the breakdown of creatine phosphate (Section 14.1.5). Lactate does not accumulate in these patients because the glycolytic rate of their muscle is much lower than normal; their glycogen cannot be mobilized. The results of NMR studies have also shown that the painful cramps in this disease are correlated with high levels of ADP (Figure 21.24). NMR spectroscopy is a valuable, noninvasive technique for assessing dietary and exercise therapy for this disease.

Figure 21.24. NMR Study of Human Arm Muscle.

Figure 21.24

NMR Study of Human Arm Muscle. The level of ADP during exercise increases much more in a patient with McArdle glycogen-storage disease (type V) than in normal controls. [After G. K. Radda. Biochem. Soc. Trans. 14(1986):522.]

By agreement with the publisher, this book is accessible by the search feature, but cannot be browsed.

Copyright © 2002, W. H. Freeman and Company.
Bookshelf ID: NBK22444

Views

  • Cite this Page
  • Disable Glossary Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...